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Abstract
Background: There has been widespread interest in the potential of combination cardiovascular medications containing
aspirin and agents to lower blood pressure and cholesterol (‘polypills’) to reduce cardiovascular disease. However, no
reliable placebo-controlled data are available on both efficacy and tolerability.
Methods: We conducted a randomised, double-blind placebo-controlled trial of a polypill (containing aspirin 75 mg,
lisinopril 10 mg, hydrochlorothiazide 12.5 mg and simvastatin 20 mg) in 378 individuals without an indication for any
component of the polypill, but who had an estimated 5-year cardiovascular disease risk over 7.5%. The primary outcomes
were systolic blood pressure (SBP), LDL-cholesterol and tolerability (proportion discontinued randomised therapy) at 12
weeks follow-up.
Findings: At baseline, mean BP was 134/81 mmHg and mean LDL-cholesterol was 3.7 mmol/L. Over 12 weeks, polypill
treatment reduced SBP by 9.9 (95% CI: 7.7 to 12.1) mmHg and LDL-cholesterol by 0.8 (95% CI 0.6 to 0.9) mmol/L. The
discontinuation rates in the polypill group compared to placebo were 23% vs 18% (RR 1.33, 95% CI 0.89 to 2.00, p=0.2).
There was an excess of side effects known to the component medicines (58% vs 42%, p=0.001), which was mostly apparent
within a few weeks, and usually did not warrant cessation of trial treatment.
Conclusions: This polypill achieved sizeable reductions in SBP and LDL-cholesterol but caused side effects in about 1 in 6
people. The halving in predicted cardiovascular risk is moderately lower than previous estimates and the side effect rate is
moderately higher. Nonetheless, substantial net benefits would be expected among patients at high risk.
Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12607000099426
Citation: PILL Collaborative Group (2011) An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (‘‘Polypill’’) in People with
Raised Cardiovascular Risk. PLoS ONE 6(5): e19857. doi:10.1371/journal.pone.0019857
Editor: James M Wright, University of British Columbia, Canada
Received January 30, 2011; Accepted April 4, 2011; Published May 25, 2011
Copyright:  2011 Rodgers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The trial was funded by The Wellcome Trust, the Health Research Council of New Zealand, the National Heart Foundation of New Zealand, the National
Health and Medical Research Council of Australia, The Brazilian Ministry of Health (Projeto Hospitais de Excelencia) and the British Heart Foundation. The polypill
and matching placebo were provided free of charge by Dr. Reddy’s Laboratories, Hyderabad, India. None of these parties had any role in study design, data
collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study. The Steering Committee
had final responsibility for the decision to submit for publication.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: arodgers@georgeinstitute.org
" For a list of members please see the Acknowledgments.
Introduction
In 2001, the World Health Organisation and The Wellcome
Trust convened a meeting of experts to discuss evidence-based and
affordable interventions for non-communicable diseases.[1] A
major impetus for the meeting was the potential of fixed-dose
combination pills containing aspirin, statin and blood pressure
lowering agents, noting ‘‘the use of a single pill could well
encourage patients to adhere to treatment as well as seriously
reduce the cost of the drugs.’’ A programme of research was
outlined, including stability and bio-availability testing followed by
assessment of short-term effects on blood pressure, cholesterol,
platelet aggregation, safety and side effects, ideally including
developing country participants. In 2002, the WHO Annual
Report outlined the substantial potential public health impact and
cost-effectiveness of scaling up access to combination treatment.[2]
An editorial that year also noted that a four component
combination pill would be expected to reduce cardiovascular risk
by about 75% among people with vascular disease.[3] In 2003 the
first full exposition of the scientific evidence for cardiovascular
combination pills was published in the medical literature.[4,5,6,7]
The ‘polypill’ term was coined and gained widespread attention, in
large part due to the recommendation to treat everyone aged over
55 years in developed countries. The proposal to target treatments
based on age alone has been highly polarizing. An alternate
approach, now recommended by major cross-disciplinary guide-
lines[8,9,10,11] and the European Medicines Agency (EMA),[12]
is to target treatments principally on the basis of global
cardiovascular risk. As noted by the EMA[12] ‘‘the terms
primary/secondary prevention have yielded their place for a
more comprehensive strategy aimed at treating patients at high
risk of cardiovascular disease…current therapeutic strategies are
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19857aimed at identifying global cardiovascular disease risk in an indi-
vidual and treating all risk factors. Global risk intervention, rather
than single risk modification is the standard of care’’.
We therefore set out to conduct the trial recommended by the
meeting of the WHO and The Wellcome Trust, assessing short-
term efficacy and side effects, among people at raised global
cardiovascular risk. The trial aimed to assess the full effects of
polypill treatment compared to placebo. Such information would
be relevant to research among people with raised cardiovascular
risk (many of whom are not currently treated as they do not have
‘hypertension’ or ‘dyslipidaemia’) and we planned this initiative as
a necessary first step before starting a large long-term trial in this
population. The trial was also planned to inform research and
treatment in people with established vascular disease, since the risk
factor reductions would be generalisable but use of placebo is not
appropriate in this group.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
We conducted a randomised controlled trial in seven countries –
Australia (n=21), Brazil (n=8), India (n=109), Netherlands
(n=102), New Zealand (n=12), United Kingdom (n=113) and
United States (n=13). Approval for the trial was obtained from
the institutional ethics committee of each centre and all
participants provided written informed consent. The trial is
registered with the Australian New Zealand Clinical Trials
Registry (ACTRN 12607000099426).
Participants
The key eligibility criteria were raised cardiovascular risk
together with no indication for or contraindication to treatment
with component medicines in the polypill. Individuals were
included if they were adults ($18 years) with a cardiovascular
disease (CVD) risk over 5 years of at least 7.5%, determined by the
Framingham risk function[13] using data on age, gender, blood
pressure, total cholesterol, HDL cholesterol, diabetes status and
cigarette smoking status (left ventricular hypertrophy was assumed
to be absent for the purpose of CVD risk calculation). A value of
7.5% on Framingham function was chosen as half the threshold
value above which all modalities are recommended in the first set
of guidelines based on absolute risk.[14] While Framingham
performs well in modern clinical practice after calibration[15] it is
nonetheless imperfect.[16] For example, it does not incorporate
some risk factors that have additional predictive value. Therefore,
those with an estimated 5-year risk of 5.0– ,7.5% from the
Framingham function were also eligible if two or more additional
risk factors were present: body mass index (BMI) .30 kg/m
2;
waist circumference .102 cm in men or .88 cm in women; heart
rate .80 beats/min; fasting glucose 5.6– ,7 mmol/L; triglycer-
ides .1.7 mmol/L; family history of premature coronary heart
disease (CHD) or ischaemic stroke in a first degree male relative
before the age of 55 years or a first degree female relative before
the age of 65 years; or glomerular filtration rate (GFR)
,60 mL/min. Uniform definitions were used for all centres.
To be included, the participants had to have no contraindica-
tion to treatment with low-dose aspirin, angiotensin-converting
enzyme (ACE) inhibitor, low-dose diuretic or statin; nor any
indication or recommendation under local guidance for
treatment with any of these medicines. The participating
countries varied in their extent of risk factor threshold-based
(eg. hypertension treatment) or absolute risk-based treatment
practices. Therefore some participants had comparatively high
risk factor levels (but moderate absolute risk), while others had
comparatively high absolute risk (but moderate risk factor
levels). Participants taking other antiplatelet, blood pressure
lowering or cholesterol lowering medicines were also excluded,
as were patients with diabetes mellitus or GFR #30 ml/min/
1.73 m
2.
Randomisation, Allocation Concealment and Study
Interventions
Eligible participants were randomised to the Red Heart Pill
(RHP, a polypill comprising a bilayered tablet containing aspirin
75 mg, lisinopril 10 mg, hydrochlorothiazide 12.5 mg and
simvastatin 20 mg) or an identical placebo, in a 1:1 ratio.
Participants, research staff and and co-ordinating centre staff
were all blinded to the allocation. Study treatment was taken once
a day in the evening with food. There was no ‘run-in’ period.
Study treatments were allocated using a central computer-based
randomisation service at The Clinical Trials Research Unit,
University of Auckland, accessible by internet, using a minimisa-
tion algorithm including age, sex and centre. Participants were
recruited from 17 October 2008 to 22 December 2009.
Regulatory delays in importing trial treatment were prolonged
and recruitment was 22 participants less than intended, since the
study medication expiry date was reached.
Concomitant Interventions
The use of concomitant open-label therapy was allowed at the
discretion of the responsible clinician. Without the need to
unblind, additional treatment with open-label therapy was
permitted –75 mg aspirin; any beta-blocker, calcium channel
blocker, angiotensin receptor blocker or alpha-blocker; 10–20 mg
lisinopril and/or 12.5 mg hydrochlorothiazide or 2.5 mg bendro-
fluazide; 10–20 mg simvastatin – if any of these treatments
became indicated during the trial. If there was a need for higher
doses of aspirin, ACE inhibitor, diuretic or simvastatin, these were
provided as open label treatment and the trial treatment was
stopped. Open-label fibrate (with the exception of gemfibrozil)
could also be added, without the need to unblind or stop the trial
treatment, provided that appropriate monitoring for rhabdomy-
olysis was instituted.
Study Procedures
Participants were seen at 2, 6 and 12 weeks after randomisation,
with a post-study follow-up appointment 4 weeks after the final 12-
week visit. At study visits, information on adherence to and
tolerability of study treatments, blood pressure, lipids and
occurrence of adverse events was obtained. Blood pressure was
recorded as the mean of two measurements made after the patient
was rested for at least 5 minutes in the seated position, using a
standardised automated sphygmomanometer that had been
validated according to the protocol of the Association for the
Advancement of Medical Instrumentation (AAMI) or British
Hypertension Society, International protocol version. Lipid
measurements were undertaken at local laboratories holding
ISO 15189 (2003 or later) accreditation. The trial was co-
ordinated by The Clinical Trials Research Unit, at The University
of Auckland which provided an internet based clinical trial
management system. An independent monitor completed bi-
monthly site visits to ensure the trial was conducted according to
the protocol, good clinical practice guidelines and relevant local
regulatory requirements. All participants provided informed
consent.
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The primary study outcomes were change in systolic blood
pressure (SBP), change in LDL-cholesterol and tolerability
(proportion who withdrew from trial treatment for any reason).
Secondary outcomes were treatment adherence (% of prescribed
treatment according to pill counts, with participants asked to
return all used blisters and unused trial treatment to study visits),
diastolic blood pressure, total cholesterol, HDL cholesterol, total
cholesterol:HDL cholesterol ratio, non-HDL cholesterol, triglyc-
erides, frequency of switching/adding open-label treatment and
estimated effects on CVD risk.
Sample Size
It was estimated that 400 participants would provide 85%
power at 2p=0.05 to detect a 0.25 mmol/l difference in LDL-
cholesterol and 80% power to detect a 4 mmHg difference in
systolic blood pressure between the intervention and control
groups, assuming standard deviations around the change from
baseline levels of 0.8 mmol/l and 14 mmHg respectively, and a
10% absolute difference in tolerability. This sample size would also
provide a 95% confidence interval width of about 6 mmHg and
0.3 mmol/L for estimates of SBP and LDL-cholesterol reductions
respectively.
Statistical analysis
Primary analysis was by intention-to-treat. Means of changes in
blood pressure and lipid values from baseline to 12 weeks
between polypill and placebo groups were compared using a 2
sample t-test. Adjusted analyses were carried out by including the
stratification factors in an analysis of covariance regression model
with change in blood pressure and lipid variable as the dependent
variable. Last observation carried forward was used for missing
data at 12 weeks, with a sensitivity analysis also based on repeated
measures using a mixed models approach to the analysis of
covariance. The proportions that withdrew from trial treatment
(tolerability) at 12 weeks between polypill and placebo groups
were compared using the chi-squared test, with those without
follow-up information assumed to have stopped study treatment.
It was determined after trial completion that there had been
mislabeling of a sequence of treatment packs that affected 14
participants who received active treatment rather than placebo.
Therefore an additional sensitivity analysis was conducted
excluding these participants. All analyses were done using SAS
[version 9.1.3].
Expected reductions in cardiovascular risk were estimated
using data from systematic reviews, which have shown that each
medication class confers approximately similar proportional
reductions in cause-specific outcomes across a wide range of
patient populations, with no major differences between agents
(after accounting for the extent of risk factor reduction for SBP
and LDL) and even when event rates vary tenfold or
more.[17,18,19,20,21] For example, aspirin produces about a
one-fifth reduction in CHD and ischaemic stroke risk in ‘primary’
and ‘secondary’ prevention.[20] There is clear evidence that the
proportional reductions in major outcomes achieved with each
treatment modality are approximately the same in the presence
or absence of other interventions[17,19,20,22] (which is expected
given the lack of interaction between treatments in terms of risk
factor reduction[23] and the epidemiology of blood pressure and
cholesterol joint effects[24,25]). Therefore, the combined effects
are best estimated by multiplying relative risks together, after
adjusting for the size of SBP and LDL-cholesterol reductions.
Thus for example, since 1 mmol/L LDL-cholesterol reduction,
10 mmHg SBP reduction and aspirin each individually lower
CHD risk by 42%[5], 22%[17] and 20%[20] respectively (ie.
RRs are 0.58, 0.78 and 0.80 respectively), the expected joint
effects of a 0.5 mmol/L LDL-cholesterol reduction, 5 mmHg
SBP reduction and aspirin would be approximately a 46% lower
CHD risk (since 0.58
0.5/1.060.78
5/1060.80=0.54, and (120.54)
6100% =46%). Combining the proportional effects with data
on current event rates (rather than event rates in trials, which are
often out of date and not representative), provides the best
estimates of expected absolute treatment effects.[26,27]
Results
A total of 378 participants were randomised into the study
(Figure 1) from 17 October 2008 to 22 December 2009. At 12
weeks, vital status was available for 373 (98.7%) of participants and
data on SBP and LDL-cholesterol levels were available for 338
(89.4%). There was good balance between randomised groups
across a range of characteristics at study entry (Table 1). The
frequency distributions for age, SBP, LDL-cholesterol and
estimated 5-year cardiovascular risk are shown in Figure 2. As
can be seen, most patients were aged between 50 and 70 years and
there was a wide range of baseline SBP and LDL-cholesterol
levels; for example according to JNC 7 criteria[28] 33% would be
regarded as having ‘hypertension’ with SBP .140 mmHg, 52%
‘pre-hypertension’ with SBP 120–139, and 14% having ‘normal’
blood pressure of SBP ,120 mmHg. Overall 22% of participants
had a 5-year cardiovascular risk of 5–7.5% by the Framingham
function (all of whom had two or more other risk factors, see
Methods), and 3% had 5-year cardiovascular risk over 20% (ie.
equivalent to the risk faced by those with previous vascular disease
events[29]).
Effects on blood pressure and cholesterol levels
Over the duration of follow-up, SBP was reduced by an average
of 9.9 (95% CI: 7.7 to 12.1) mmHg compared to the placebo
group, while LDL-cholesterol was reduced by an average of 0.8
(95% CI: 0.6 to 0.9) mmol/L (both p,0.0001, see Figure 3).
Treatment differences were achieved at two weeks and maintained
throughout follow-up. Overall effect estimates were not impor-
tantly altered by adjusted analyses or by the exclusion of
participants receiving mislabeled treatment packs (SBP reduction
10.4, 95% CI 8.1 to 12.7 mmHg and LDL-cholesterol reduction
0.8, 95% CI 0.7 to 0.9 mmol/L).
There was also a reduction in DBP of 5.3 mmHg (95% CI 3.9
to 6.7, p,,0.001), in total cholesterol of 0.8 mmol/L (95%CI,
0.7–1.0, p,0.001) and in triglycerides of 0.2 mmol/L (95%CI
0.120.3, p=0.001). There was no clear effect on HDL
(0.02 mmol/L increase, 95% CI 20.04 to 0.04, p=0.9).
Tolerability and side effects
Overall through the 12 weeks, 44 (23%) in the polypill group
compared to 33 (18%) in the placebo group discontinued
treatment (RR 1.33, 95% CI 0.89 to 2.00 p=0.2). Most dis-
continuations occurred early: 29 (66%) of the 44 discontinuations
in the polypill group occurred by week 6. The main reasons for
discontinuation of trial treatment by randomised group are shown
in Table 2.
A total of 110 (58%) of the polypill group and 79 (42%) of the
control group reported side effects (p=0.001). Most side effects did
not necessitate stopping treatment. The excesses were mainly
attributable to the well known side effects of aspirin [gastric
irritation and/or bleeding tendency occurring in 32 (17%) of the
polypill group and 11 (6%) of the placebo group] and of ACE
inhibitor-based blood pressure lowering [cough and/or light
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polypill group and 20 (11%) of the placebo group]. Most side
effects were apparent early on: at week 2, side effects were
reported by 41% vs 26% (77 vs 49 people), whereas only 14% vs
11% (26 vs 20) reported new side effects in week 6 and only 4% vs
5% (7 vs 10) reported new side effects at week 12. A total of 353
participants answered the question ‘‘what trial treatment do you
think you have been taking?’’ at the end of follow-up. The answer
was correct for 79% (139/177) of people allocated polypill and for
59% (104/176) of people allocated placebo (p,0.0001 for
difference).
Eight serious adverse events were reported, four in each group
(polypill group - chest pain, newly diagnosed Type 2 diabetes,
removal of wisdom teeth, syncope; placebo group – syncope,
depression, transient ischaemic attack, hip fracture). There were
no deaths, major vascular events, major bleeds or episodes of
gastrointestinal ulceration.
Overall, the proportion of scheduled treatment taken according
to self-reported pill counts was 82% for the polypill group and
86% for the placebo group (p=0.1). Open-label therapy was
required infrequently during follow-up: for blood pressure
lowering (4 vs 3 participants), cholesterol lowering (0 vs 4) and
antiplatelet therapy (2 vs 3).
Predicted effects on cardiovascular risk
The estimated effects on cardiovascular events and other major
outcomes for those continuing treatment long-term are shown in
Table 3. One would expect an approximate 60% reduction in
CHD and ischaemic stroke risk, little overall effect on haemor-
rhagic stroke risk (the beneficial effects of blood pressure lowering
balancing out the adverse effects of aspirin) and a 50% increase in
the risk of extra-cranial bleeding. The net effects of such treatment
on any major outcome thus importantly depend on the event rates
of each component outcome. In a patient group at similar risk to
the average in this trial one would expect more than a halving in
CVD events and about a halving in any major event (stroke, CHD
or major bleed). Over 5 years of treatment, about 1 in 18 would
benefit in terms of avoiding a major event, with the large majority
of the net benefit due to the SBP and LDL-reduction. Among
untreated individuals with a history of coronary artery disease,
event rates are higher, particularly for CHD and ischaemic
stroke.[29,30] Hence compared to a lower-risk population, the
proportional reductions for the composite of any major event are a
little greater and the absolute benefits are much greater, being of
clear clinical importance for each component. Overall about 1 in 4
high risk people would be predicted to avoid a major event over 5
years.
Figure 1. CONSORT flow chart. This figure shows the flow of patients through the trial according to the criteria recommended in the CONSORT
Guidelines.
doi:10.1371/journal.pone.0019857.g001
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These results show that treatment with this polypill achieved
sizeable reductions in SBP and LDL-cholesterol. These risk factor
reductions, together with the findings of systematic reviews of the
component medicines, indicate that this treatment can be expected to
more than halve cardiovascular risk. Starting treatment with this
polypill caused side effects sufficient to stop treatment in about 1 in 20
people. Other less serious side effects occurred in about 1 in 8 people,
with most becoming apparent after just a few weeks of treatment.
There are several limitations of this study. The relatively short
follow-up precluded assessment of the long-term rates of drop-out.
It is well recognized, for example, that gastric bleeding due to
aspirin can occur months or even years after starting treatment.
However, placebo-controlled trials of the separate components of
this polypill show that most long-term drop-out is not related to
side effects (i.e. drop-out rates in the placebo group are much more
than half those in the active group) and that long-term dropout
rates are much lower than those observed early after starting
treatment. Nonetheless, the effects on cardiovascular events
estimated here only apply to those staying on treatment long-
term. While characteristic side effects were the only ones evident,
the design precluded definitive attribution of which component
caused which side effects. The patient population represented a
relatively narrow group, having raised cardiovascular risk and no
existing indications for any of the medicines. However, history of
symptomatic cardiovascular disease does not modify the extent of
risk factor reductions, which are likely to be broadly generali-
sable.[4,5] Finally, the predicted reductions in cardiovascular risk
are based on reductions in risk factor levels and, while it appears
Table 1. Baseline characteristics.
Red Heart Pill
n=189
Placebo
n=189
Cardiovascular risk factors in Framingham score
Age (yrs) 61.2 (7.2) 61.6 (7.2)
Male 153 (81%) 152 (80%)
Blood pressure (mmHg) 132/80 (13/9) 136/81 (14/9)
LDL-cholesterol (mmol/L) 3.7 (0.9) 3.6 (0.9)
Total cholesterol (mmol/L) 5.6 (1.1) 5.4 (1.0)
HDL (mmol/L) 1.2 (0.3) 1.3 (0.4)
Smoker (or quit within the last year) 79 (42%) 74 (39%)
Other cardiovascular risk factors*
Body mass index .30 kg/m
2, waist circumference .102 cm in men
or .88 cm in women
88 (47%) 90 (48%)
Heart rate .80 beats/min 48 (25%) 46 (24%)
Fasting glucose 5.6– ,7 mmol/L 55 (29%) 60 (32%)
Family history of premature coronary heart disease or ischaemic stroke 87 (46%) 77 (41%)
Triglycerides .1.7 mmol/L 69 (37%) 53 (28%)
Glomerular filtration rate (GFR) ,60 mL/min 18 (10%) 23 (12%)
At least 2 of the above* 120 (63%) 117 (62%)
Cardiovascular risk
5-year cardiovascular risk - Framingham function 10% (4.1%) 11% (4.5%)
10-yr fatal cardiovascular risk – SCORE function 4.3% (5.0%) 4.9% (5.4%)
Medications
Prescribed or over-the-counter medicines 59 (31%) 43 (23%)
Vitamin and/or mineral capsules/tablets 43 (23%) 37 (20%)
Other dietary supplements 34 (18%) 31 (16%)
Any other complementary or alternative medicine 5 (3%) 7 (4%)
Current lifestyle factors
Moderate physical exercise in last 7 days (mins) 211 (240) 256 (279)
Vigorous physical exercise in last 7 days (mins) 23 (104) 16 (49)
Formal exercise programme 4 (2%) 5 (3%)
Seeing a dietician or other nutritional counsellor or on a weight control programme 1 (1%) 1 (1%)
Smoking cessation programme 4 (2%) 2 (1%)
Other
Currently drink alcohol once a week or more (on most weeks for at least the last year) 132 (69%) 142 (75%)
Data are mean (sd) or n (%).
*Participants with Framingham 5-yr CVD risk 5–7.5% were eligible for the trial if they had at least two such factors.
doi:10.1371/journal.pone.0019857.t001
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most or all of the benefits,[17,18,19,20,21,31,32] these are
nonetheless indirect estimates.
Two previous trials have assessed the effects of polypill
treatment compared to control on risk factor reductions,
tolerability and estimated cardiovascular risk, and their results
are compared with the current study and Wald and Law’s original
predictions in Table 4. The Indian Polycap Study (TIPS)
randomized 2,053 individuals without cardiovascular disease,
aged 45–80 years and with one or more risk factors, to 12 weeks
treatment with the Polycap (hydrochlorothiazide 12?5 mg, aten-
olol 50 mg, ramipril 5 mg, simvastatin 20 mg and aspirin
100 mg), or to one of eight other groups: aspirin alone, simvastatin
alone, hydrochlorothiazide alone, three combinations of the two
blood pressure lowering drugs, three blood pressure lowering
drugs alone, or three blood pressure lowering drugs plus
aspirin.
[23] This design allowed demonstration that the risk factor
reductions from each treatment modality were essentially the same
in the presence and absence of other treatments.
[23] Malekzadeh
et al conducted a double-blind randomised placebo controlled trial
in residents of Golestan, Iran.[33] Following an 8-week placebo
run-in period, 475 participants, aged 50 to 79 years, without
cardiovascular disease, hypertension or hyperlipidaemia were
randomised to fixed-dose combination therapy (aspirin 81 mg,
enalapril 2.5 mg, atorvastatin 20 mg and hydrochlorothiazide
12.5 mg) or placebo for a period of 12 months. Both trials had
relatively high non-attendance at final follow-up: 16% in TIPS
and 27% in the Malekzadeh et al trial (22% in the control group
and 33% in the polypill group, p=0.02 for difference), compared
to 1% in the current trial. Therefore TIPS and in particular the
Malekzadeh et al trial were more prone to bias, especially when
assessing side effects since these are often associated with loss to
follow-up.
The risk factor reductions in TIPS were comparable in size to
those observed in the current trial, even though the Polycap
contained an additional blood pressure lowering agent. At the end
of 12weeks,66/412 (16%) peopleinthePolycapgroup hadstopped
taking study treatment compared to 34/189 (18%) in the current
trial. TIPS could not estimate total excess (ie. placebo-corrected)
side effects, since each comparison group contained at least one
active component. However it did report no clear difference in side
effect rates between the different active groups. The risk factor
reductions in the Malekzadeh trial were notably lower than both
TIPS and the current trial, but this may well be due to low baseline
levels (which were differential between the groups for blood
pressure, p,0.0001), loss to follow-up and non-adherence. The
Figure 2. Baseline frequency distributions of age, LDL-cholesterol, SBP and 5-year cardiovascular risk. This figure shows the frequency
distribution of participants according to their baseline levels of age, LDL-cholesterol, SBP and 5-year cardiovascular risk.
doi:10.1371/journal.pone.0019857.g002
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(8%) participants reporting reluctance to take study treatment and
only 2/475 (0.4%) reporting adverse drug reactions. This is likely to
beinlargepartattributabletothe combinedimpactoflosstofollow-
up, under-reporting and non-adherence.
One further active-controlled trial has recently been completed,
in which 216 individuals from Sri Lanka who were aged over 50
years old if female and over 40 years if male, and who had an
estimated 10-year total CVD risk score .20%, based on WHO
CVD risk prediction charts, were randomized to a polypill
(containing 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and
12.5 mg hydrochlorothiazide) or to standard practice.[34] The
results suggested similar reduction in risk factors and predicted
cardiovascular risk in both groups.
This is the first trial to empirically test Wald and Law’s
predictions of side effects attributable to a polypill: Table 4 shows
that the observed excess of side effects is considerably greater than
that predicted. The risk factor reductions seen in the current trial
are also about half the size predicted by Wald and Law,[6] mostly
because those estimates were based on higher baseline risk factor
levels, use of a more potent statin and an extra blood pressure
lowering agent. Interestingly however the estimated reductions in
CHD and stroke from this polypill are only about 25–30% smaller
than those of Wald and Law. This is because of the diminishing
Figure 3. Blood pressure and LDL-cholesterol changes. This figure shows the changes in blood pressure and LDL-cholesterol over the 12 week
trial period, according to active (dark line) or placebo (grey line).
doi:10.1371/journal.pone.0019857.g003
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Reported side effects of sufficient severity to
discontinue study treatment*
Reported side effects not necessitating
discontinuation of study treatment
Red Heart Pill Placebo P-value Red Heart Pill Placebo P-value
n% n % n% n%
Gastric irritation 6 3% 1 1% 0.06 23 12% 6 3% 0.0005
Increased bleeding tendency 0 0% 0 0% 4 2% 1 1% 0.2
Cough 3 2% 2 1% 0.7 19 10% 3 2% 0.0002
Light headed/dizziness/hypotension 7 4% 2 1% 0.09 28 15% 8 4% 0.0002
Muscle pain or weakness 1 1% 2 1% 0.6 13 7% 14 7% 0.9
Headache 1 0% 0 0% 4 2% 3 2% 0.6
Diarrhoea 0 0% 0 0% 4 2% 5 3% 0.8
Fatigue 3 2% 2 1% 0.7 13 7% 10 5% 0.4
Abdominal pain 0 0% 0 0% 4 2% 1 1% 0.2
Constipation 0 0% 0 0% 10 5% 4 2% 0.08
Flatulence 0 0% 0 0% 6 3% 5 3% 0.7
Other side effect 13 6% 12 6% 0.8 39 21% 28 15% 0.07
Patient choice 0 0% 3 2% 0.08
Total** 34 18% 24 13% 0.2 81 43% 59 31% 0.003
*participants without relevant follow-up data at 12 weeks (10 vs 9) were assumed to have stopped treatment in the definition of tolerability as the primary trial
outcome, which was therefore 44 (23%) vs 33 (18%).
**for patients discontinuing treatment, the total is a direct sum as data reflect the main reason for stopping for each patient. For patients not discontinuing treatment,
the total refers to the number of people reporting one or more side effects.
doi:10.1371/journal.pone.0019857.t002
Table 3. Estimated reductions in cardiovascular risk for those remaining on treatment.
Treatment
Risk factor
reduction Proportional risk reduction*
No. needed to treat for
5 yrs to prevent 1 major
event
CHD
Ischaemic
stroke
Haem-
orrhagic
stroke
"
Major
extra-cranial
bleed
Any major
event -
moderate risk
pop
n1
Any major
event - high
risk pop
n1
Moderate
risk pop
n1
High risk
pop
n1
Blood pressure
lowering
16
10 mmHg
lower SBP
22% 41% 41% 0% 26% 29% 40 9
Cholesterol
lowering
5
0.8 mmol/L
lower LDL
35% 23% 0% 0% 26% 27% 40 9
Aspirin
14 Not applicable 20% 17% 239% 254% 8% 13% 125 20
All three
treatments
60% 62% 18% 254% 46% 53% 18 4
*See Methods. Proportional effects from systematic reviews[5,17,20] and given by (1-RR)*100%, where RR is relative risk. Proportional effects of BP and cholesterol
lowering emerge fully after about a year and may vary slightly by age; those for 60–69 year group shown here.
"Proportional effects of blood pressure lowering on haemorrhagic stroke and ischaemic stroke assumed to be the same as for total stroke, as most trials have not
reported on stroke subtypes. No effect of statins on haemorrhagic stroke is assumed, reflecting the overall results from statin trials.
8
1Any major event = CHD, ischaemic stroke, haemorrhagic stroke or major extra-cranial bleed. Assumes pre-treatment annual rates of CHD, ischaemic stroke,
haemorrhagic stroke and major extra-cranial bleed of 1.0%, 0.6%, 0.1%, and 0.2% (ie. moderate risk - the average for this trial population[13,20,51,52]) and of 4.0%,
3.0%, 0.3% and 0.4% (high risk - expected for people with symptomatic coronary artery disease[29,53]). These event rates will vary according to many factors, especially
age and disease history.
Footnote: Trials indicate this formulation would also affect other vascular and related outcomes, but in most patient populations these would have less clinical impact
due to lower incidence and/or severity. Blood pressure lowering would reduce heart failure incidence (by about a quarter), headache and renal events; [17,54,55,56]
aspirin would reduce venous thromboembolism.[57;, 1994 #1665] An approximately neutral overall effect on diabetes incidence is expected: ACE-inhibitors reduce
risk[58] but this would be offset by small increases in risk conferred by the low-dose thiazide[59] and statin.[60] Effects on major non-vascular events would also occur,
but similarly the absolute effects would mostly be small: the thiazide would reduce renal calculus and fracture, and increase gout;[17,54] the statin will cause
rhabdomyolysis (in less than 1 per 10,000 patient years[61]) and long-term aspirin can be expected to reduce gastrointestinal cancer by about one-third and all solid
cancers by about one-fifth.[62]
doi:10.1371/journal.pone.0019857.t003
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and the multiplicative benefits of adding different treatment
modalities ie. less risk reduction from one modality leaves ‘more to
slice off’ for the next modality.
What are the implications of these findings for research and
clinical practice? Among patients at low-to-moderate global
cardiovascular risk, further work is required on polypill formula-
tions and target patient populations. This trial suggests that the
short-term tolerability of a polypill is not as good as previous
predictions or trials have suggested, although still nonetheless
causing no symptoms in 5 out of 6 people treated. Most side
effects, including virtually all major ones, would be due to aspirin,
and the inclusion of aspirin in combination treatment provides
modest net benefits,[20] although recent data showing that aspirin
reduces the incidence of cancer will change this risk-balance
equation back again. Nonetheless, even among patients at
moderately elevated risk, such as the average in this trial (which
is considerably higher than the risk faced by individuals with, for
example, uncomplicated hypertension, dyslipidaemia or diabetes)
the absolute benefits of aspirin would be small. For such
individuals whose risk has first been reduced by blood pressure
and cholesterol lowering, aspirin would only avoid a major event
in every thousand or more patients per year. Polypills based on
blood pressure and cholesterol lowering agents are therefore
required, along with research on their benefits and risks compared
to usual care. An area of controversy will be whether such trials
should assess hard cardiovascular endpoints (taking many years to
complete) or just measure side effects and BP and LDL reduction,
given the conclusive evidence of the event reduction from
individual treatments, the lack of interaction between the
treatments, and the finding that most or all of the benefits are
due to the extent of BP or LDL reduction. [17,19,20,22] One
further issue is that although efficacy of blood pressure and
cholesterol lowering has been clearly established well below
historical ‘hypertension’ and ‘dyslipidaemia’ thresholds,[21,35,36]
indications currently approved by regulatory authorities and much
clinical practice is restricted to those with ‘hypertension’ or
‘dyslipidaemia’ (regardless of the level of cardiovascular risk).
Among patients with a history of occlusive vascular disease,
further evidence on efficacy for individual medication classes is not
required, since this has been established with clinical trials
involving many tens of thousands of patient over half a century.
All major cross-disciplinary guidelines[9,23,37] recommend some
form of blood pressure lowering, cholesterol lowering and
antiplatelet therapy in patients with vascular disease. Research is
therefore only required on the comparative roles of polypill-based
treatment compared to usual care in delivering these therapies
long-term. People with previous symptomatic vascular disease are
relatively easily identified, more motivated to take treatment and
account for almost half of all major cardiovascular events. Among
this group the benefits of this combination therapy substantially
outweigh the side effects, and one could reasonably expect similar-
sized benefits in asymptomatic patients at equivalently high risk,
who comprise about 5% of the adult population.[38] Yet the vast
majority of highest-risk people globally do not receive such
treatment long-term. In economically developed countries most
are now prescribed recommended medicines after an acute event,
but many do not continue: only one- to two-thirds of people with a
history of vascular disease take antiplatelet, blood pressure
lowering and statin therapy long-term.[39,40,41,42] In econom-
ically developing countries, where 80% of the global burden
of cardiovascular disease occurs,[43] very few receive these
medicines in the short or long-term.[44,45] With current
approaches, these treatment gaps are closing very slowly.[46]
Increasing access to treatment is a potentially highly cost-effective
strategy[47,48,49] and alone could achieve most of WHO’s goals
for reducing non-communicable disease.[50]
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Table 4. Comparison with previous polypill studies.
Formulation
Blood pressure
(mmHg)
LDL-cholesterol
(mmol/l)
Placebo-corrected absolute
excess of side effects**
Estimated
proportional risk
reduction
Baseline
level Reduction
Baseline
level Reduction
Sufficient to
stop treatment
in short term
Causing any
symptoms CHD Stroke
Wald and
Law*[4,5,6]
Statin (eg. simvastatin 40 mg),
three K strength blood
pressure drugs, aspirin 75 mg
150/90 20/11 4.8 1.8 2% 8–15% 86% 74%
TIPS[23] Simvastatin 20 mg,
hydrochlorothiazide 12?5 mg,
atenolol 50 mg, ramipril 5 mg,
aspirin 100 mg
134/85 7/6 3.0 0.7 n/a n/a 62% 48%
Malekzadeh
et al [33]
Atorvastatin 20 mg, enalapril
2.5 mg, hydrochlorothiazide
12.5 mg, aspirin 81 mg
128/79 5/2 3.0 0.5 n/a n/a 34% 21%
Current trial Simvastatin 20 mg,
hydrochlorothiazide 12?5 mg,
lisinopril 10 mg, aspirin 75 mg
134/81 10/5 3.7 0.8 5% 16% 60% 56%
*Estimated rather than observed risk factor reductions and side effects. Predictions for formulation without folic acid.
**Not estimable for TIPS due to lack of placebo control and side effects not reported reliably in Malekzadeh et al trial (see Discussion). Side effects ‘causing any
symptoms’ refers to those observed in 12 weeks treatment for current trial and predictions for both short and long term treatment by Wald and Law. This excess was
estimated at 8% for a formulation containing a thiazide, angiotensin II receptor blocker and calcium channel blocker and 15% for a formulation containing a thiazide,
beta-blocker, and ACE inhibitor.
doi:10.1371/journal.pone.0019857.t004
Can a Polypill Safely Halve Cardiovascular Risk?
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19857Checklist S1 CONSORT Checklist
(PDF)
Acknowledgments
The Program to Improve Life and Longevity (PILL) Collabora-
tive Group
Steering and Writing Committee
Anthony Rodgers (Chair), The George Institute for Global Health,
Sydney, NSW, Australia
Anushka Patel, The George Institute for Global Health, Sydney, NSW,
Australia
Otavio Berwanger, Hospital do Corac ¸a ˜o, Sao Paolo, Brazil
Michiel Bots, Julius Center for Health Sciences and Primary Care,
Utrecht, The Netherlands
Richard Grimm, Berman Center for Outcomes and Clinical Research,
Minneapolis, Minnesota, USA
Diederick E. Grobbee, Julius Center for Health Sciences and Primary
Care, Utrecht, The Netherlands
Rod Jackson, School of Population Health, The University of Auckland,
Auckland, New Zealand
Bruce Neal, The George Institute for Global Health, Sydney, NSW,
Australia
Jim Neaton, Division of Biostatistics, University of Minnesota,
Minneapolis, Minnesota, USA
Neil Poulter, International Centre for Circulatory Health, London,
United Kingdom
Natasha Rafter, formerly Clinical Trials Research Unit, The University
of Auckland, Auckland, New Zealand
P Krishnam Raju, Care Hospitals, Hyderabad, Andhra Pradesh, India
Srinath Reddy, The Public Health Foundation of India, New Delhi,
India
Simon Thom, International Centre for Circulatory Health, Imperial
College, London, United Kingdom
Stephen Vander Hoorn, formerly Clinical Trials Research Unit, The
University of Auckland, Auckland, New Zealand
Assisted by Ruth Webster, The George Institute for Global Health,
Sydney, NSW, Australia.
International Co-ordinating Centre – The Clinical Trials
Research Unit, Auckland
Project Manager: Angela Wadham
Research Fellow: Vanessa Selak, Natasha Rafter
Statistican: Steve Vander Hoorn, Joy Jiang
Data Management: Rina Prasad, John Faatui, Tamsin Scott, Amanda
Milne
IT: Barry Gray, Colleen Ng, Johan Strydom
Australia centre - The George Institute for Global Health,
Sydney
Principal Investigator: Anushka Patel
Project Manager: Bindu Patel, Paula Zeman
Monitor: Oscar-Hazel Donaldson
Investigators: Joseph Canalese, Patrick Groenstein, Kumara Mendis,
David Sullivan
Local Co-ordinators: Kerry Kearns, Nicole Li, Toni Monico, Evelyn
Nangle, Chloe Runeckles
Brazil centre - Hospital do Corac ¸a ˜o, Sao Paolo
Principal Investigator: Otavio Berwanger
Project Manager: Ligia Nasi Laranjeira, Anna Maria Buchler
Monitor: Andrea Di Vanna
Investigators: Alexandre Biasi, Helio Penna Guimaraes, Nora Falconi
Local Co-ordinators: Cyntia Da Silva, Elaine Bastos De Menezes
India centre TheGeorge Institute for Global Health,Hyderabad
Principal Investigator: Anushka Patel
Project Manager: Bindu Patel
Monitor: M.Abdul Salam
Investigators: Ashok Kumar Dash, Kalyana Chakravarthy, Gundala
Anil Krishna, Panchangam Sampath Kumar, Ravi Jayam
Local Co-ordinators: Mohammed Abdul Azeem Imran, Vemulakonda
Sushma, Hari Obulesu, Syed Fayaz, Kasparam Mahesh
New Zealand centre - The Clinical Trials Research Unit,
Auckland
Principal Investigator: Anthony Rodgers
Project Manager and Monitor: Angela Wadham
Investigators: Fiona McLean, James Smith, Christine Forster, Malcolm
Lowe, Harley Aish, John Cameron
Local Co-ordinator: Denise Miller
The Netherlands centre - Julius Center for Health Sciences
and Primary Care, Utrecht
Principal Investigators: Diederick E Grobbee and Michiel Bots
Project Manager: Lizeth Vendrig
Monitor: Gonnie Vierstra, Ischa Vissers, Jacobien Vermande, Karin
Groot
Investigators: Deborah Font-Julia, Hans Zuidema, Marcel VanDyk,
Ron Peters, Sara Rafi, Suthesh Sivapalaratnam
Local Co-ordinators: Janneke van den Brink, Liselotte Kok, Lydeke
Zwart, Trees Groenveld, Hanneke Basart
UK centre - International Centre for Circulatory Health,
London,
Principal Investigators: Simon Thom and Neil Poulter
Project Manager and Monitor: Thiagarajah Sasikaran
Investigators: Filomena Paciello and Judith Mackay
Local Co-ordinators: Hannah Lanzon-Miller, Jill Bunker, Candida
Coghlan, Rachel Chapman, Rebecca Webb, Wendy Callister
USA centre - Berman Center for Outcomes and Clinical
Research, Minneapolis
Principal Investigator: Richard Grimm
Project Manager: Rachel Moor
Monitor: Margaret Dimond
Investigators: Mobin Malik
Local Co-ordinators: Alexa Camarena-Michel
Dr Reddy’s liaison
Raghu Cidambi, Asit Datta, Haranath Robby, Arvind Ananthakrish-
nan, Prakash Shenthar Mahalinga, Neetta Mohit, Rajesh Dubey, Rekha
Sinha
All members would like to acknowledge and thank the trial participants
Author Contributions
Conceived and designed the experiments: AR AP OB MB RG DG RJ BN
JN NP NR PR SR ST SV. Performed the experiments: AR AP OB MB
RG DG RJ BN JN NP NR PR SR ST SV. Analyzed the data: SV. Wrote
the paper: AR AP OB MB RG DG RJ BN JN NP NR PR SR ST SV.
References
1. World Health Organization (2002) Secondary prevention of non-communicable
disease in low and middle income countries through community-based and
health service interventions. World Health Organization - Wellcome Trust
meeting report 1 - 3 August 2001, Geneva.
2. World Health Organization (2002) The World Health Report 2002. Reducing
risks,promoting healthy life WHO, ed. Geneva: WHO.
3. Yusuf S (2002) Two decades of progress in preventing vascular disease. Lancet
360: 2–3.
4. Law MR, Wald NJ, Morris JK, Jordan RE (2003) Value of low dose
combination treatment with blood pressure lowering drugs: analysis of 354
randomised trials. British Medical Journal 326: 1427–1431.
5. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low
density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic
review and meta-analysis. British Medical Journal 326: 1423–1430.
6. Wald NJ, Law MR (2003) A strategy to reduce cardiovascular disease by more
than 80%. British Medical Journal 326: 1419–.
7. Wald NJ, Law MR (2001) Formulation For The Prevention Of Cardiovascular
Disease. WO.
8. Fourth joint task force of the European Joint Society of Cardiology and Other
Societies on cardiovascular disease prevention in clinical practice (2007)
European guidelines on cardiovascular disease prevention in clinical practice:
executive summary. European Heart Journal 28: 2375–2414.
9. British Cardiac Society, British Hypertension Society, Diabetes UK, Heart UK,
Primary Care Cardiovascular Society, et al. (2005) JSB2: Joint British Societies’
guidelines on prevention of cardiovascular disease in clinical practice. Heart 91:
1–52.
10. The National Vascular Disease Prevention Alliance (Diabetes Australia KHA
National Heart Foundation of Australia, and National Stroke Foundation of
Can a Polypill Safely Halve Cardiovascular Risk?
PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19857Australia) (2004) Consensus statement for the prevention of vascular disease.
Australian Family Physician 33.
11. New Zealand Guidelines Group (2003) Evidence-based best practice guideline.
The assessment and management of cardiovascular risk New Zealand
Guidelines Group.
12. European Agency for the Evaluation of Medicinal Products (EMA) (2008)
Guideline on the Evaluation of Medicinal Products for Cardiovascular Disease
Prevention.
13. Anderson K, Wilson P, Odell P, Kannel W (1991) An updated coronary risk
profile. A statement for health professionals. Circulation 83: 356–362.
14. Jackson R, Barham P, Bills J, Birch T, McLennan L, et al. (1993) Management
of raised blood pressure in New Zealand: a discussion document. British Medical
Journal 307: 107–110.
15. Riddell T, Wells S, Jackson R, Lee AW, Crengle S, et al. (2010) Performance of
Framingham cardiovascular risk scores by ethnic groups in New Zealand:
PREDICT CVD-10. New Zealand Medical Journal 123: 50–61.
16. (2007) Using Framingham for primary prevention cardiovascular risk assess-
ment. Therapeutics Letter, 63/ MAR - APR.
17. Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in
the prevention of cardiovascular disease: meta-analysis of 147 randomised trials
in the context of expectations from prospective epidemiological studies. British
Medical Journal 338: b1665–.
18. Blood Pressure Lowering Treatment Trialists C (2008) Effects of different
regimens to lower blood pressure on major cardiovascular events in older and
younger adults: meta-analysis of randomised trials. British Medical Journal 336:
1121–1123.
19. Cholesterol Treatment Trialists’ (CTT) Collaboration (2005) Efficacy and safety
of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056
participants in 14 randomised trials of statins. Lancet 366: 1267–1278.
20. Antithrombotic Trialists Collaboration (2009) Aspirin in the primary and
secondary prevention of vascular disease: collaborative meta-analysis of
individual participant data from randomised trials. The Lancet 373: 1849–1860.
21. Law M, Wald N (2002) Risk factor thresholds: their existence under scrutiny.
British Medical Journal 324: 1570–1576.
22. Law MR, Wald NJ, Morris JK (2003) Lowering blood pressure to prevent
myocardial infarction and stroke: a new preventive strategy. British Medical
Journal 7.
23. The Indian Polycap Study, Yusuf S, Pais P, Afzal R, Xavier D, et al. (2009)
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without
cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet
373: 1341–1351.
24. Asia Pacific Cohort Studies C (2005) Joint effects of systolic blood pressure and
serum cholesterol on cardiovascular disease in the Asia Pacific region.
Circulation 112: 3384–3390.
25. Prospective Studies C, Lewington S, Whitlock G, Clarke R, Sherliker P, et al.
(2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure:
a meta-analysis of individual data from 61 prospective studies with 55,000
vascular deaths. Lancet 370: 1829–1839.
26. Glasziou PP, Irwig LM (1995) An evidence based approach to individualising
treatment. British Medical Journal 311: 1356–1359.
27. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A (2005) Treatment
with drugs to lower blood pressure and blood cholesterol based on an
individual’s absolute cardiovascular risk. The Lancet 365: 434–441.
28. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report Journal
of the American Medical Association 289: 2560–2572.
29. Law MR, Watt HC, Wald NJ (2002) The underlying risk of death after
myocardial infarction in the absence of treatment. Arch Intern Med 162:
2405–2410.
30. Steg PG, Goldberg RJ, Gore JM, Fox KAA, Eagle KA, et al. (2002) Baseline
characteristics, management practices, and in-hospital outcomes of patients
hospitalized with acute coronary syndromes in the Global Registry of Acute
Coronary Events (GRACE). American Journal of Cardiology 90: 358–363.
31. Boissel JP, Gueyffier F, Boutitie F, Pocock S, Fagard R. Apparent effect on blood
pressure is only partly responsible for the risk reduction due to antihypertensive
treatments.
32. Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood
pressure reduction: a meta-analysis. [Erratum appears in Lancet 2002 Jan
26;359(9303):360] The Lancet Volume 358: 1305–1315.
33. Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, et al. (2010) A
pilot double-blind randomised placebocontrolled trial of the effects of fixed-dose
combination therapy (‘polypill’) on cardiovascular risk factors. International
Journal of Clinical Practise 64: 1220–1227.
34. Soliman E, Mendis S, Dissanayake W, Somasundaram N, Gunaratne P, et al.
(2011) A Polypill for primary prevention of cardiovascular disease: A feasibility
study of the World Health Organization. Trials 12: 3.
35. Jackson R, Lawes C, Bennett D, Milne R, Rodgers A (2005) Treatment with
drugs to lower blood pressure and blood cholesterol based on an individual’s
absolute cardiovascular risk. Lancet 365: 434–441.
36. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, et al. (2011)
Antihypertensive treatment and secondary prevention of cardiovascular disease
events among persons without hypertension: a meta-analysis. JAMA 305:
913–922.
37. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, et al.
(2003) European guidelines on cardiovascular disease prevention in clinical
practice: Third Joint Task Force of European and other Societies on
Cardiovascular Disease Prevention in Clinical Practice (constituted by
representatives of eight societies and by invited experts). European Journal of
Cardiovascular Prevention & Rehabilitation 10: S1–S78.
38. Wells S, Broad J, Jackson R, Wells S, Broad J, et al. (2006) Estimated prevalence
of cardiovascular disease and distribution of cardiovascular risk in New
Zealanders: data for healthcare planners, funders, and providers. New Zealand
Medical Journal 119: U1935.
39. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyo ¨ra ¨la ¨ K, et al. (2009)
Cardiovascular prevention guidelines in daily practice: a comparison of
EUROASPIRE I, II, and III surveys in eight European countries. The Lancet
373: 929–940.
40. Webster RJ, Heeley EL, Peiris DP, Bayram C, Cass A, et al. (2009) Gaps in
cardiovascular disease risk management in Australian general practice. Medical
Journal of Australia 191: 324–329.
41. Kumar A, Fonarow GC, Eagle KA, Hirsch AT, Califf RM, et al. (2009)
Regional and practice variation in adherence to guideline recommendations for
secondary and primary prevention among outpatients with atherothrombosis or
risk factors in the United States: a report from the REACH Registry. Critical
Pathways in Cardiology: A Journal of Evidence-Based Medicine 8: 104–111.
42. World Health Organisation (2003) Adherence to long-term therapies. Evidence
for action. Geneva: WHO.
43. Beaglehole R, Ebrahim S, Reddy S, Vou ˆte J, Leeder S. Prevention of chronic
diseases: a call to action. The Lancent 370: 2152–2157.
44. Mendis S, Abegunde D, S Y, Ebrahim S, Shaper G, et al. (2005) WHO study on
Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-
PREMISE). Bulletin of the World Health Organization 83: 820–828.
45. Sharma KK, Gupta R, Agrawal A, Roy S, Kasliwal A, et al. (2009) Low use of
statins and other coronary secondary prevention therapies in primary and
secondary care in India. Vasc Health Risk Manag 5: 1007–1014.
46. Selak V, Rafter N, Parag V, Tomlin A, Hoorn SV, et al. (2009) Cardiovascular
treatment gaps: Closing, but slowly. New Zealand Medical Journal 122: 41–49.
47. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, et al. (2003)
Effectiveness and costs of interventions to lower systolic blood pressure and
cholesterol: a global and regional analysis on reduction of cardiovascular-disease
risk. Lancet 361: 717–725.
48. Gaziano TA, Opie LH, Weinstein MC (2006) Cardiovascular disease prevention
with a multidrug regimen in the developing world: a cost-effectiveness analysis.
Lancet 368: 679–686.
49. Goldberg RJ, Currie K, White K, Brieger D, Steg PG, et al. (2004) Six-month
outcomes in a multinational registry of patients hospitalized with an acute
coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]).
The American journal of cardiology 93: 288–293.
50. Lim S, Gaziano TA, Gakidou E, Srinath Reddy K, Farzadfar F, et al. (2007)
Prevention of cardiovascular disease in high-risk individuals in low-income and
middle-income countries: health effects and costs. Lancet 370: 2054–2062.
51. Longstreth GF (1995) Epidemiology of hospitalization for acute upper
gastrointestinal hemorrhage: a population-based study. American Journal of
Gastroenterology 90: 206–210.
52. Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL (2002) Hospitalization
and mortality rates from peptic ulcer disease and GI bleeding in the 1990s:
relationship to sales of nonsteroidal anti-inflammatory drugs and acid
suppression medications. Am J Gastroenterol 97: 2540–2549.
53. Fox KAA, Steg PG, Eagle KA, Goodman SG, Anderson FA, et al. (2007)
Decline in rates of death and heart failure in acute coronary syndromes, 1999-
2006. JAMA 297: 1892–1900.
54. Law M, Morris JK, Jordan R, Wald N, Law M, et al. (2005) Headaches and the
treatment of blood pressure: results from a meta-analysis of 94 randomized
placebo-controlled trials with 24,000 participants. Circulation 112: 2301–2306.
55. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial
infarction and stroke: a new preventive strategy. [Review] [188 refs].
56. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, et al. (2009) Lowering
blood pressure reduces renal events in type 2 diabetes. Journal of the American
Society of Nephrology 20: 883–892.
57. Antiplatelet Trialists’Collaboration (1994) Collaborative overview of randomised
trials of antiplatelet therapy–III: Reduction in venous thrombosis and
pulmonary embolism by antiplatelet prophylaxis among surgical and medical
patients. British Medical Journal 308: 235–246.
58. Andraws R, Brown DL, Andraws R, Brown DL (2007) Effect of inhibition of the
renin-angiotensin system on development of type 2 diabetes mellitus (meta-
analysis of randomized trials). American Journal of Cardiology 99: 1006–1012.
59. Law M, Wald N, Morris J (2003) Lowering blood pressure to prevent myocardial
infarction and stroke: a new preventive strategy. Health Technology Assessment
(Winchester, England) 7: 1–94.
60. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. (2010) Statins and
risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
The Lancet 375: 735–742.
61. Law MR, Rudnicka AR (2006) Statin Safety: A Systematic Review. The
American Journal of Cardiology 97: S52–S60.
62. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, et al. (2011)
Effect of daily aspirin on long-term risk of death due to cancer: analysis of
individual patient data from randomised trials. The Lancet 377: 31–41.
Can a Polypill Safely Halve Cardiovascular Risk?
PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e19857